Aspira Womens HealthAWHL +7.07%36 PS Ratio is 1.86 as of Jul. 06, 2026, which is 87% below its 10-year median of 14.59. GuruFocus rates AWHL with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Aspira Womens Health ranks better than 64.85% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Aspira Womens Health's share price is $0.42.
Aspira Womens Health's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.23. Hence, Aspira Womens Health's PS Ratio for today is 1.86.
The historical rank and industry rank for Aspira Womens Health's PS Ratio or its related term are showing as below:
AWHL'
s PS Ratio Range Over the Past 10 Years
Min: 0.05 Med: 14.59 Max: 198.48
Current: 1.86
During the past 13 years, Aspira Womens Health's highest PS Ratio was 198.48. The lowest was 0.05. And the median was 14.59.
AWHL's PS Ratio is ranked better than 64.85% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.855
vs AWHL: 1.86
Aspira Womens Health Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Aspira Womens Health was -61.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -36.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -15.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -3.30% per year.
During the past 13 years, Aspira Womens Health's highest 3-Year average Revenue per Share Growth Rate was 130.60% per year. The lowest was -91.30% per year. And the median was -2.00% per year.
Back to Basics: PS Ratio
Aspira Womens Health (OTCPK:AWHL) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Aspira Womens Health PS Ratio Related Terms
Aspira Womens Health PS Ratio Historical Data
* Premium members only.
The historical data trend for Aspira Womens Health's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Aspira Womens Health's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's PS Ratio distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Aspira Womens Health's Share Price of today is $0.42. Aspira Womens Health's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.23.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Aspira Womens Health (AWHL) has a PS Ratio of 1.86 as of Jul. 06, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Aspira Womens Health and its competitors. This is 87% below median its historical median of 14.59. Over the past decade, Aspira Womens Health's PS Ratio has ranged from 0.05 to 198.48. According to the industry distribution chart, Aspira Womens Health ranks #71 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 35.1%.
Is Aspira Womens Health's PS Ratio too high?
Aspira Womens Health's current PS Ratio of 1.86 is 87% below median its 10-year median of 14.59. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 198.48. The Medical Diagnostics & Research industry median PS Ratio is 2.86. Aspira Womens Health's value of 1.86 is 34.9% below this industry median. Based on the distribution chart, Aspira Womens Health ranks #71 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Aspira Womens Health has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Womens Health's PS Ratio compare to MDXH and BIOQ?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Womens Health ranks #71 out of 202 companies for PS Ratio. This puts Aspira Womens Health in the upper half of its industry. The industry median PS Ratio is 2.86. Aspira Womens Health's value of 1.86 is 34.9% below this benchmark. Historically, Aspira Womens Health's own PS Ratio has ranged from 0.05 to 198.48 over the past decade. While the company's 10-year median is 14.59 vs. the industry median of 2.86, Aspira Womens Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.86, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspira Womens Health's current PS Ratio of 1.86 is 34.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Aspira Womens Health and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspira Womens Health's current PS Ratio is 1.86, which is 87% below median its own 10-year median of 14.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Womens Health stock overvalued right now?
Based on GuruFocus' analysis, Aspira Womens Health (AWHL) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $0.42 — trading 50% above its estimated fair value. The current PS Ratio is 1.86, which is 87% below median its 10-year median of 14.59 and 34.9% below the Medical Diagnostics & Research industry median of 2.86. Aspira Womens Health's overall GF Score™ is 36/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Aspira Womens Health (AWHL), the current PS Ratio is 1.86 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Womens Health (AWHL) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued.
The current stock price of $0.42 is trading 50% above its estimated GF Value™ of $0.28.
GuruFocus considers Aspira Womens Health to be Significantly Overvalued.
Key valuation signals for AWHL:
PS Ratio: 1.86 (87% below median its 10-year median of 14.59)
GF Value™: $0.28 vs. price of $0.42 (50% above fair value)
Industry Position: 34.9% below the Medical Diagnostics & Research median (#71 of 202)
No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.
36GF Score
Get the complete analysis for AWHL
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AWHL has been successfully added to your 
